PTHLH and small cell lung carcinoma: More recently, the combination of anti-PTHrP treatment and zoledronic acid, a third generation bisphosphonate, was shown to better control the progression of bone metastases in natural killer cell-depleted immunosuppressed mice inoculated with SBC-5 human small cell lung cancer cells than either agent alone, thereby suggesting the usefulness of such dual-target therapy in treating lung tumor-affected patients [57].